Cybin (NEO: CYBN), a leading Toronto-based biotech and life sciences company focused on psychedelic pharmaceutical therapies, today made its debut on the global public markets and is now trading on the NEO Exchange under the symbol “CYBN.” The company, which focuses on psychedelic drug development, unique delivery mechanisms, improved novel compounds and protocols, recently closed a C$45 million subscription receipt financing in relation to its reverse takeover transaction. This signified the largest subscription receipt financing in the Canadian psychedelic sector. “Today marks a meaningful milestone for our company, as our shares begin trading on the NEO Exchange under the ticker symbol CYBN,” said Cybin CEO Doug Drysdale. “The NEO Exchange shares our passion for innovation and provides a broad platform for our next stage of growth. Cybin is heading into a very active period with the pending start of a phase 2 clinical study of sublingual psilocybin for the potential treatment of major depressive disorder. This work will take place in Jamaica with the University of West Indies. Our listing on NEO gives us increased access to capital, enhanced visibility with the investment community and, most importantly, a greater opportunity to bring innovative new treatment options to market.”
To view the full press release, visit https://ibn.fm/k015p
About Cybin Inc.
Cybin is a life sciences company advancing psychedelic pharmaceutical treatments for various psychiatric and neurological conditions. Cybin is developing technologies and delivery systems aiming to improve bioavailability to achieve the desired effects of psychedelics at low dosage levels. The new delivery systems are expected to be studied through clinical trials to confirm safety and efficacy. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://ibn.fm/Cybin
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
